PharmaShots | Incisive News in 3 Shots

Subscribe Now

priority review

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin...

November 12, 2021

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

November 12, 2021

Novartis Reports the US FDA and EMA's Acceptance of sBLA for Kymriah (tisagenlecleucel) and Granted Priority Review to Treat R/R Follicular Lymphoma

Novartis Reports the US FDA and EMA's Acceptance of sBLA for Kymriah (tisagenlecleucel) and Granted Priority Review to Treat R/R F...

October 29, 2021

Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19

Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19

October 14, 2021

Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

August 18, 2021

Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC

Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC

August 10, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us